FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential
March 7th 2022Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.
Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma
Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.
Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma
January 24th 2022Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.
Full-Dose Pacritinib Bests Ruxolitinib for Patients With Cytopenic Myelofibrosis
December 14th 2021Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib.
Mount Sinai Receives NCI Grant to Study Anal Cancer Screening in High-Risk Women
August 10th 2021The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million by the National Cancer Institute for a large-scale study to evaluate anal cancer screening in high-risk women who have been previously diagnosed with human papillomavirus infection.